Alsagaby Suliman A, Alhumaydhi Fahad A
Department of Medical Laboratories Sciences, Faculty of Applied Medical Sciences, Majmaah University, Majmaah, Kingdom of Saudi Arabia. E-mail.
Saudi Med J. 2019 Apr;40(4):317-327. doi: 10.15537/smj.2019.4.23598.
Chronic lymphocytic leukemia (CLL) is an incurable malignant disease of B-lymphocytes characterized by drastically heterogeneous clinical courses. Proteomics is an advanced approach that allows a global profiling of protein expression, providing a valuable chance for the discovery of disease-related proteins. In the last 2 decades, several proteomics studies were conducted on CLL to identify aberrant protein expression underpinning the malignant transformation and progression of the disease. Overall, these studies provided insights into the pathology and prognosis of CLL and reveal protein candidates with the potential to serve as biomarkers and/or therapeutic targets of the tumor. The major findings reported in these studies are discussed here.
慢性淋巴细胞白血病（CLL）是一种无法治愈的B淋巴细胞恶性疾病，其临床病程具有极大的异质性。蛋白质组学是一种先进的方法，可对蛋白质表达进行全面分析，为发现疾病相关蛋白质提供了宝贵机会。在过去20年中，针对CLL开展了多项蛋白质组学研究，以确定支撑该疾病恶性转化和进展的异常蛋白质表达。总体而言，这些研究为CLL的病理学和预后提供了见解，并揭示了有潜力作为该肿瘤生物标志物和/或治疗靶点的蛋白质候选物。本文将讨论这些研究报告的主要发现。
